NO2881536T3 - - Google Patents

Info

Publication number: NO2881536T3
Authority: NO; Norway

Application number

NO14196403A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2014-12-04

Publication date

2018-06-30

2014-12-04 Application filed filed Critical

2018-06-30 Publication of NO2881536T3 publication Critical patent/NO2881536T3/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Mechanical Treatment Of Semiconductor (AREA)

NO14196403A 2012-04-06 2014-12-04 NO2881536T3 (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261621461P	2012-04-06	2012-04-06

Publications (1)

Publication Number	Publication Date
NO2881536T3 true NO2881536T3 (lt)	2018-06-30

Family

ID=49325295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO14196403A NO2881536T3 (lt)	2012-04-06	2014-12-04

Country Status (29)

Country	Link
US (3)	US20130273053A1 (lt)
EP (2)	EP3366307B1 (lt)
JP (3)	JP6366571B2 (lt)
KR (2)	KR102142508B1 (lt)
CN (2)	CN121401408A (lt)
AU (3)	AU2013267909B2 (lt)
BR (1)	BR112014024793A2 (lt)
CA (2)	CA3087933A1 (lt)
CL (1)	CL2014002694A1 (lt)
CY (1)	CY1120736T1 (lt)
DK (2)	DK3366307T3 (lt)
ES (2)	ES2894944T3 (lt)
HR (1)	HRP20180671T1 (lt)
HU (1)	HUE036930T2 (lt)
IL (2)	IL234991B (lt)
IN (1)	IN2014KN02324A (lt)
LT (1)	LT2833907T (lt)
MX (2)	MX357540B (lt)
NO (1)	NO2881536T3 (lt)
NZ (2)	NZ629675A (lt)
PL (2)	PL3366307T3 (lt)
PT (1)	PT2833907T (lt)
RS (1)	RS57266B1 (lt)
RU (2)	RU2655299C2 (lt)
SI (1)	SI2833907T1 (lt)
SM (1)	SMT201800253T1 (lt)
TR (1)	TR201806939T4 (lt)
WO (1)	WO2013180834A2 (lt)
ZA (1)	ZA201408100B (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3725811A3 (en) *	2011-05-04	2021-01-27	Omeros Corporation	Compositions for inhibiting masp-2 dependent complement activation
KR102339315B1 (ko) *	2012-06-18	2021-12-15	오메로스 코포레이션	다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
WO2014144542A2 (en) *	2013-03-15	2014-09-18	Omeros Corporation	Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
KR20230073346A (ko)	2016-11-28	2023-05-25	추가이 세이야쿠 가부시키가이샤	리간드 결합 활성을 조정 가능한 리간드 결합 분자
TW202323287A (zh) *	2016-11-28	2023-06-16	日商中外製藥股份有限公司	包含抗原結合域與運送部分的多胜肽
WO2018186322A1 (en) *	2017-04-03	2018-10-11	Chugai Seiyaku Kabushiki Kaisha	Anti-masp-1 antibodies and methods of use
AU2018376309B2 (en)	2017-11-28	2025-09-18	Chugai Seiyaku Kabushiki Kaisha	Ligand-binding molecule having adjustable ligand-binding activity
KR20200089311A (ko)	2017-11-28	2020-07-24	추가이 세이야쿠 가부시키가이샤	항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
CN117964683A (zh)	2018-05-29	2024-05-03	奥默罗斯公司	Masp-2抑制剂和使用方法
EP3807312A4 (en)	2018-05-30	2022-07-20	Chugai Seiyaku Kabushiki Kaisha	POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT
EP4003327A4 (en) *	2019-07-31	2023-08-02	Biocryst Pharmaceuticals, Inc.	Dosing regimens for oral complement factor d inhibitors
JP7721142B2 (ja)	2019-12-04	2025-08-12	オメロスコーポレーション	Ｍａｓｐ－２阻害剤および使用方法
AU2020396565C1 (en)	2019-12-04	2025-05-15	Omeros Corporation	MASP-2 inhibitors and methods of use
AU2020398241B2 (en)	2019-12-04	2025-03-20	Omeros Corporation	MASP-2 inhibitors and methods of use
JP7634082B2 (ja)	2020-08-18	2025-02-20	オメロスコーポレーション	補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
CN114295594B (zh) *	2021-12-06	2023-09-19	贵州理工学院	一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器
CR20240271A (es) *	2021-12-10	2024-08-12	Omeros Corp	Anticuerpos que se unen al dominio serina proteasa de masp-2
WO2024251199A1 (zh) *	2023-06-09	2024-12-12	舒泰神（北京）生物制药股份有限公司	特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
DE69030172T2 (de)	1990-01-26	1997-06-19	Immunomedics Inc	Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5837242A (en)	1992-12-04	1998-11-17	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US20030186419A1 (en) *	1999-12-02	2003-10-02	Jensenius Jens Christian	Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) *	2001-07-23	2006-05-09	Intel Corporation	Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
KR101101261B1 (ko)	2002-07-19	2012-01-04	인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링	생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
EP1601377A4 (en) *	2003-02-21	2009-07-15	Genentech Inc	METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE
WO2005075665A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US20050169921A1 (en) *	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
US7803931B2 (en) *	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
NZ612578A (en)	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
ATE419671T1 (de) *	2006-07-31	2009-01-15	Fiat Ricerche	Durch eine fluidströmung betätigbarer elektrischer generator
ES2628973T3 (es)	2007-05-31	2017-08-04	University Of Washington	Mutagénesis inducible de genes diana
CN102164960A (zh) *	2008-09-26	2011-08-24	罗氏格黎卡特股份公司	双特异性抗-egfr/抗-igf-1r抗体
WO2010080833A1 (en) *	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
JP2012519555A (ja) *	2009-03-05	2012-08-30	スミスアンドネフューインコーポレーテッド	大腿骨頚ガイドワイヤーの位置決め用のシステム、方法、及び装置
BR112012001070B1 (pt) *	2009-07-17	2022-05-03	Omeros Corporation	Composição de polipeptídeo associado à ficolina e uso da mesma
CN102958535A (zh) *	2009-11-05	2013-03-06	亚力史剑桥公司	阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
US8795973B2 (en) *	2010-11-29	2014-08-05	University of Leceister	Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
CN110075294A (zh)	2011-04-08	2019-08-02	莱斯特大学	用于治疗与masp-2依赖性补体活化相关的状况的方法

2013
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 SM SM20180253T patent/SMT201800253T1/it unknown
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en not_active Ceased
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
- 2013-04-05 MX MX2018008658A patent/MX388278B/es unknown
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2013-04-05 CN CN202511539101.0A patent/CN121401408A/zh active Pending
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active Active
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active Active
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending

Also Published As

Publication number	Publication date
ES2894944T3 (es)	2022-02-16
HK1206996A1 (en)	2016-01-22
JP2021001199A (ja)	2021-01-07
IN2014KN02324A (lt)	2015-05-01
JP2018162307A (ja)	2018-10-18
RU2018114903A (ru)	2019-03-04
JP2015514117A (ja)	2015-05-18
WO2013180834A2 (en)	2013-12-05
EP3366307A1 (en)	2018-08-29
JP6815355B2 (ja)	2021-01-20
AU2018200721A1 (en)	2018-02-22
CN104661676A (zh)	2015-05-27
RU2018114903A3 (lt)	2021-08-12
EP3366307B1 (en)	2021-07-28
SMT201800253T1 (it)	2018-07-17
KR20200097808A (ko)	2020-08-19
IL234991A0 (en)	2014-12-31
DK2833907T3 (en)	2018-05-28
CA3087933A1 (en)	2013-12-05
CA2869326C (en)	2021-09-21
KR102318623B1 (ko)	2021-11-02
SI2833907T1 (en)	2018-07-31
ZA201408100B (en)	2022-05-25
EP2833907B1 (en)	2018-02-28
PL3366307T3 (pl)	2022-03-07
AU2013267909B2 (en)	2018-03-01
IL274721A (en)	2020-07-30
RU2655299C2 (ru)	2018-05-24
HUE036930T2 (hu)	2018-08-28
RS57266B1 (sr)	2018-08-31
AU2013267909A1 (en)	2014-11-27
HRP20180671T1 (hr)	2018-07-13
LT2833907T (lt)	2018-06-11
AU2020204163A1 (en)	2020-07-09
KR102142508B1 (ko)	2020-08-10
NZ727063A (en)	2021-10-29
WO2013180834A3 (en)	2014-04-03
JP6366571B2 (ja)	2018-08-01
US20220242972A1 (en)	2022-08-04
US20130273053A1 (en)	2013-10-17
MX2014012045A (es)	2015-05-15
TR201806939T4 (tr)	2018-06-21
NZ781091A (en)	2022-04-29
AU2018200721B2 (en)	2020-03-26
IL234991B (en)	2020-06-30
EP2833907A2 (en)	2015-02-11
DK3366307T3 (da)	2021-11-01
MX388278B (es)	2025-03-18
BR112014024793A2 (pt)	2019-08-27
CA2869326A1 (en)	2013-12-05
RU2014144621A (ru)	2016-05-27
CY1120736T1 (el)	2019-12-11
NZ629675A (en)	2017-02-24
CN121401408A (zh)	2026-01-27
PT2833907T (pt)	2018-05-29
IL274721B (en)	2022-04-01
CL2014002694A1 (es)	2015-08-28
KR20150003785A (ko)	2015-01-09
MX2018008658A (es)	2021-10-19
PL2833907T3 (pl)	2018-08-31
ES2670668T3 (es)	2018-05-31
MX357540B (es)	2018-07-13
EP2833907A4 (en)	2016-03-16
US20190382505A1 (en)	2019-12-19

Publication	Publication Date	Title
BR112014017635A2 (lt)	2017-06-20
BR112014017614A2 (lt)	2017-06-20
BR112014019206A2 (lt)	2017-06-20
BR112014017625A2 (lt)	2017-06-20
BR112014017659A2 (lt)	2017-06-20
BR112014019052A2 (lt)	2017-06-20
BR112014017592A2 (lt)	2017-06-20
BR112014018373A2 (lt)	2017-06-20
BR112014017607A2 (lt)	2017-06-20
BR112014017646A2 (lt)	2017-06-20
BR112014017638A2 (lt)	2017-06-20
BR112013027865A2 (lt)	2017-01-03
BR112014017609A2 (lt)	2017-06-20
NO2881536T3 (lt)	2018-06-30
BR112014017644A2 (lt)	2017-06-20
BR112014018747A2 (lt)	2017-06-20
BR112014017634A2 (lt)	2017-06-20
BR112014019903A2 (lt)	2017-06-20
BR112014013184A8 (lt)	2017-06-27
BR112014017618A2 (lt)	2017-06-20
BR112014017647A2 (lt)	2017-06-20
BR112014019415A2 (lt)	2017-06-20
BR112014017623A2 (lt)	2017-06-20
BR112014020806A2 (lt)	2017-06-20
BR112014017627A2 (lt)	2017-06-20